251 related articles for article (PubMed ID: 33510493)
1. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy.
Maharjan R; Wang JW; Shrestha IK
J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
3. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
[TBL] [Abstract][Full Text] [Related]
5. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Anjum N; Nabi Z; Alam MA
J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
[TBL] [Abstract][Full Text] [Related]
6. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
Front Immunol; 2021; 12():738788. PubMed ID: 34721403
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
Front Immunol; 2019; 10():3069. PubMed ID: 31998325
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment of idiopathic membranous nephropathy.
Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
[TBL] [Abstract][Full Text] [Related]
9. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
[No Abstract] [Full Text] [Related]
12. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
13. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
14. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
[TBL] [Abstract][Full Text] [Related]
15. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.
Conversano E; Debiec H; Colucci M; Emma F; Ronco P; Vivarelli M
Pediatr Nephrol; 2024 Jan; 39(1):305-308. PubMed ID: 37466865
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for idiopathic membranous nephropathy: who can benefit?
Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
[TBL] [Abstract][Full Text] [Related]
17. [Expert consensus on the application of rituximab in the treatment of membranous nephropathy].
Nephrology Expert Panel of the Peking University Health Science Center
Zhonghua Nei Ke Za Zhi; 2022 Mar; 61(3):282-290. PubMed ID: 35263969
[TBL] [Abstract][Full Text] [Related]
18. Treatment of membranous nephropathy: time for a paradigm shift.
Ruggenenti P; Fervenza FC; Remuzzi G
Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of PLA
Schmidt T; Schulze M; Harendza S; Hoxha E
J Nephrol; 2021 Apr; 34(2):603-606. PubMed ID: 33026632
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
